Novel 3D matrix will allow predictive and effective breast cancer treatment
On average, more than 90% of the breast cancer drugs fail in clinical trials with real patients and each failed drug costs 1.4 billion euro. Tekes has now provided a funding of 0.5 million euros for Aalto University and the University of Helsinki to develop and commercialize a novel preclinical model to enhance drug development processes and personalized medicine approaches.
鈥淏y combining cutting edge nanotechnology and advanced cancer biology, we have successfully developed extracellular matrix, a material that mimics the cellular environment of the cancer tissues, keeping the structure of the tumour tissues unchanged and alive for a couple of weeks鈥 time and thereby allowing correct and personalized drug identification for cancer treatment鈥, explains Research Fellow Nonappa from Aalto University.
鈥淭he 3D matrix not only maintains tissue identity, but also heterogeneity of the tumour, which is a key feature of a preclinical model to predict correctly the real drug responses and thus accelerate the process of getting more effective treatments for the breast cancer patients鈥, adds postdoctoral researcher Pauliina Munne from the University of Helsinki.
Need for individualized treatments
In Finland, there are 5000 new breast cancer patients yearly, and globally one in every eight women undergo breast cancer diagnosis at one point in her lifetime. Despite significant increase in the five-year survival rates after detection, breast cancer remains one of the leading causes of death in women.
鈥淲e have failed to treat breast cancer with the current 鈥渙ne size fits all鈥 treatment approaches. The present preclinical models including cell lines and animal tests are faulty, too simplistic and poorly predictive. This is due to their insufficient ability to mimic the original tumour cellular identity and heterogeneity鈥, describes Nonappa.
鈥淭he tumour consists of diverse cell types. If you try to grow a tumour sample on a Petri dish in a laboratory, only certain cell types will survive. The rest will either die or transform to another cell type. Drug response studies are usually performed using immortal cell lines, which represent only one or few cell types. These models are poorly predicting the drug responses in patient, which is evident from the high number of failed drugs in clinical trials鈥, adds Munne.
The successful commercialization team consists of inter-disciplinary team including internationally acclaimed material science group from Aalto University and breast cancer experts from the University of Helsinki together with an established network between Hospital district of Helsinki and Uusimaa, securing the availability of tumour samples.
Further information:
Nonappa
Research Fellow
Aalto University
tel. +358 50 593 1480
nonappa@aalto.fi
Pauliina Munne
Postdoctoral researcher
University of Helsinki
tel. +358 29 412 5494
pauliina.munne@helsinki.fi
Read more news
H盲meenlinna Art Museum鈥檚 exhibition brings artworks to life through film
H盲meenlinna Art Museum will open a new exhibition Kehyskertomuksia: 24 fps / Reframing Cinema, produced in collaboration with the Aalto University Department of Film ELO.
New macular degeneration treatment the first to halt disease鈥檚 progression
Aalto University researchers have uncovered a promising way to treat the dry form of the age- related macular degeneration (AMD) in the early diagnosis phase that could potentially stop its progression. The novel treatment approach aims to strengthen the protective mechanisms of affected cells using heat, explains Professor Ari Koskelainen.
AI use makes us overestimate our cognitive performance
New research warns we shouldn鈥檛 blindly trust Large Language Models with logical reasoning 鈥撯 stopping at one prompt limits ChatGPT鈥檚 usefulness more than users realise.